|XHQHX -- USA Fund|| |
USD 24.90 0.20 0.80%
Dr. Daniel R. Omstead, Ph.D., is a President, Trustee of HQ Healthcare Investors. Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to HQH, HQL and THQ. Dr. Omstead is also President of HQH, HQL and THQ and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restrictedventure portfolios within HQH, HQL and THQ. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including IlluminOss Medical, Inc., Magellan Diagnostics, Inc., Dynex Corporationrationration, Insightra Medical, Inc., Neurovance, Inc., EBI Life Sciences, Inc. and Euthymics Biosciences, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporationrationration and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies
Age: 63 President Since 2003
Omstead holds Ph.D. and Master Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.